Design, Synthesis, and Evaluation of New 2-Arylpropanoic Acid-l-Tryptophan Derivatives for Mitigating Cisplatin-Induced Nephrotoxicity.

Ming Yuan, Huai Wang, Mingjun Yu, Sen Yao, Risheng Yao

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ming YuanSchool of Food and Biological Engineering, Hefei University of Technology, Hefei 230601, China.ORCID 0009-0001-9523-5018

Huai WangSchool of Food and Biological Engineering, Hefei University of Technology, Hefei 230601, China.

Mingjun YuSchool of Food and Biological Engineering, Hefei University of Technology, Hefei 230601, China.ORCID 0000-0003-1029-5538

Sen YaoSchool of Food and Biological Engineering, Hefei University of Technology, Hefei 230601, China.

Risheng YaoSchool of Food and Biological Engineering, Hefei University of Technology, Hefei 230601, China.

Funding

The Key Program of Natural Science Research by Education Department of Anhui Province of China 2022AH052409

6 · The paper itself

Abstract

Cisplatin (CIS) is a widely used chemotherapeutic agent that is highly effective against various cancers. However, its clinical application is frequently limited by its substantial nephrotoxic side effects. The gastrin-releasing peptide receptor (GRPR), a critical regulator in inflammatory diseases, has been identified as a promising therapeutic target. Our previous studies have demonstrated that the GRPR antagonists PD176252 and RH-1402 can mitigate CIS-induced nephrotoxicity through anti-inflammatory mechanisms. Based on these findings, we designed and synthesized a series of 2-arylpropanoic acid-L-tryptophan derivatives to enhance the therapeutic effects. Among these compounds,

Indexed as

CisplatinDrug DesignKidney DiseasesTryptophanAnimalsAntineoplastic AgentsCell SurvivalCytokinesMiceMolecular Docking SimulationAntineoplastic AgentsCisplatinCytokinesTryptophan2-arylpropanoic acidanti-inflammatorycisplatingastrin-releasing peptide receptornephrotoxicityPD176252

Identifiers

PMID40509291

DOI10.3390/molecules30112400

PMCPMC12156107

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.